Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-ALPV in Advanced Solid Tumors
NCT05229900Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of sgn-alpv in ovarian cancer, endometrial cancer (EC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by Seagen Inc. Primary endpoints: Number of participants with adverse events (AEs), Number of participants with laboratory abnormalities and 2 more. Started Apr 2022; status: terminated.
02
Drugs
sgn-alpv
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)gastric cancer (GC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05229900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229900.